

# IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA

Paula Piñero<sup>1,2</sup> · Oriol Juanola<sup>1,2,3</sup> · Ana Gutiérrez<sup>1,2,4</sup> · Pedro Zapater<sup>1,2,5</sup> · Paula Giménez<sup>1,2</sup> · Anna Steinert<sup>6,7</sup> · Laura Sempere<sup>2,4</sup> · José M. González-Navajas<sup>1,2</sup> · Jan H. Niess<sup>6,7</sup> · Rubén Francés<sup>1,2,3</sup>

Received: 26 April 2017 / Revised: 1 August 2017 / Accepted: 20 August 2017  
© Springer-Verlag GmbH Germany 2017

## Abstract

Interleukin IL26 supports killing of microbes and the innate sensing of bacterial-derived DNA (bactDNA). We evaluated the relationship between IL26 serum levels and bactDNA translocation in Crohn's disease (CD). We ran a prospective study on CD patients in remission. IL26 common polymorphisms, serum cytokines and complement protein, amplified-bactDNA, and anti-TNF- $\alpha$  were evaluated. In vitro PBMC analysis was performed. Three hundred and thirteen patients were included (mean CDAI:  $83.6 \pm 32.8$ ; mean fecal calprotectin:  $55.4 \pm 35.3$   $\mu\text{g/g}$ ). A

total of 106 patients (33.8%) showed bactDNA and 223 patients (71%) had a *varIL26* genotype. BactDNA significantly correlated with increased IL26 levels compared with bactDNA-negative patients. PBMCs from *varIL26* patients significantly reduced *E. coli* killing capacity compared with *wtIL26*-genotyped patients. The stimulation with a recombinant IL26 protein reduced pro-inflammatory cytokines in response to *E. coli* in the *varIL26* cell supernatants. Serum anti-TNF- $\alpha$  levels in *varIL26* vs *wtIL26*-genotyped patients on biologics were significantly lower in the presence of bactDNA. Cells from *varIL26* vs *wtIL26*-genotyped patients cultured with *E. coli* DNA and infliximab showed a significant decrease in free anti-TNF- $\alpha$  concentration. A *varIL26* genotype was associated with the initiation of anti-TNF- $\alpha$  in CD patients during the 6-month follow-up. *IL26* polymorphisms may prevent bactDNA clearance and identify CD patients with a worse inflammatory evolution and response to therapy.

Paula Piñero and Oriol Juanola are *first authors*

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00109-017-1585-6>) contains supplementary material, which is available to authorized users.

✉ Rubén Francés  
frances\_rub@gva.es

- <sup>1</sup> CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
- <sup>2</sup> Instituto ISABIAL, Hospital General Universitario de Alicante, Alicante, Spain
- <sup>3</sup> Departamento Medicina Clínica, Universidad Miguel Hernández, San Juan de, Alicante, Spain
- <sup>4</sup> Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain
- <sup>5</sup> Servicio de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain
- <sup>6</sup> University Clinic of Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland
- <sup>7</sup> Departments of Biomedicine and Gastroenterology and Hepatology, Basel University, Switzerland Basel, Basel, Switzerland

## Key messages

- BactDNA translocation in CD is associated with an increased risk of relapse.
- IL26 is sensitive to bactDNA and modulates the inflammatory response in CD patients.
- The *varIL26* genotype is associated with reduced PMN capacity to kill bacteria.
- A *varIL26* genotype is associated with decreased levels of anti-TNF- $\alpha$  in CD patients.
- IL26 may help explain the role of bactDNA as a risk factor of flare in CD patients.

**Keywords** Crohn's disease · Bacterial translocation · Interleukin 26

## Introduction

The translocation of bacterial DNA (bactDNA) into the blood is a frequent and clinically relevant event in up to 40% of patients with Crohn's disease (CD) [1, 2], which is driven by an unbalanced interaction between the intestinal microbiota and the mucosal immune system in a genetically predisposed individual [3–6], leading to a sustained inflammatory milieu in these patients [7, 8]. The translocation of bactDNA has been associated with increased disease activity, and it has been identified as an independent risk factor of flare in the short term [9].

Interleukin 17-producing helper T ( $T_H$ ) cells are involved in defense against fungi and extracellular bacterial infections, are increased in numbers in active CD patients [10], and produce cytokines associated with disease activity [11]. Interleukin IL26 is produced by  $T_H17$  cells in colonic lesions of patients with active inflammatory bowel disease (IBD) [12]. IL26 is a 19 kDa member of the IL-20 cytokine family that signals through the IL-10R2-IL-20R1 heterodimeric receptor [13]. It facilitates killing of microbes, senses extracellular bactDNA, and promotes a potent proinflammatory response by inducing plasmacytoid dendritic cells (pDCs) to secrete interferon (IFN)- $\alpha$  [14]. The clearance of bactDNA might be compromised in the absence of IL26 availability and account for disease flares. Actually, the blockade of IL-17A with the human anti-IL-17A monoclonal antibody secukinumab leads to increased disease activity in CD patients [15].

Genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in the *IL26* gene that were associated with IBD [16, 17] and other inflammatory disorders, such as rheumatoid arthritis [18]. As IL26 promotes bacterial killing [14], we hypothesize that CD patients with a variant (var) *IL26* genotype may not adequately clear bactDNA fragments, facilitating upheld levels of proinflammatory mediators such as TNF- $\alpha$ . This might contribute to the significantly reduced levels of anti-TNF- $\alpha$  observed in patients with bactDNA compared to patients without bactDNA, considered as an indirect evidence of increased drug consumption in these patients [8], and would support the role of bactDNA translocation as a risk factor for relapse in CD patients [9].

In the present study, we have investigated the role of IL26 on the inflammatory and anti-TNF- $\alpha$  levels in response to bactDNA translocation in a large series of CD patients in remission.

## Material and methods

### Patients and study design

In this prospective, observational study, CD patients in remission, diagnosed and followed at Hospital General Universitario de Alicante, Spain, were consecutively

included. Remission was defined as a CDAI < 150 and absence of clinical symptoms of relapse. Only patients, who did not change their established therapy in the previous month, were included. The diagnosis of CD was established according to standard clinical, endoscopic, histological, and radiographical criteria [19]. Patients treated with antibiotics in the previous 4 weeks, patients with signs of active infection, and those who refused to sign informed consent to participate in the study were excluded. The incidence of *IL26* gene polymorphisms in the control population was obtained from The 1000 Genomes Project Consortium [20] ([www.1000genomes.org](http://www.1000genomes.org)). The Ethics Committee of Hospital General Universitario de Alicante approved the study protocol.

Usual clinical and analytical variables in the management of CD patients, including fecal calprotectin, were recorded at baseline in all patients. All patients were Caucasian of Mediterranean ethnicity and were classified according to the Montreal classification [21]. All included patients received diaries to record symptoms 1 week prior to inclusion and sample collection.

Blood samples were obtained for routine hematological and biochemical studies at inclusion and inoculated in aerobic and anaerobic blood culture bottles, 10 ml each. Simultaneously, two separate blood samples were inoculated under aseptic conditions in rubber-sealed sterile Vacutainer SST II and K3E tubes, respectively (BD Diagnostics, Erembodegem, Belgium), which were never exposed to free air. Peripheral blood mononuclear cells (PBMCs) were isolated using Biocoll Separating Solution (Biochrom GmbH, Berlin, Germany) according to manufacturer's instructions.

### Identification of bactDNA fragments and IL26 genotyping

Genomic DNA was isolated from  $5 \times 10^6$  cells with the QIAamp DNA Blood Minikit (Qiagen, Hilden, Germany). BactDNA was identified by running a broad-range PCR with universal eubacterial primers of a conserved region of *16SrRNA* gene followed by partial nucleotide sequencing, as previously described [22].

We studied rs2870946, rs1558744, and rs7134599 SNPs in the *IL26* gene, located on chromosome 12q15. After extraction of genomic DNA from the peripheral blood with the QIAamp DNA Blood Mini Kit (Qiagen), partial amplification of the regions containing the different polymorphisms was performed using the following specific primers: rs2870946 forward 5'-GCTTAATTGCTCCAGCCATGC-3', reverse 5'-GAAATGGGAAGGCACAGGCTA-3'; rs1558744 forward 5'-CTCCCACCCACCCCAATTTA-3', reverse 5'-ACGG GTTGACCTGTTCAGAG-3'; and rs7134599 forward 5'-AGAAGTGAGCTTGCTTGCTGTGT-3', reverse 5'-GCAG GATCAAAATGTCAAGCAGT-3'. The PCR products, of 174, 182, and 153 bp length, respectively, were purified using

ExoSAP-IT PCR Product Cleanup (Affymetrix). The incidence of polymorphisms was detected by nucleotide sequencing of PCR products using the same primers as for the amplification. Subsequently, the sequencing process was performed in the sequencing service of Secugen S.L. The results were analyzed with FinchTV software version 1.5 (Geospiza). Patients bearing either one or more of the studied SNPs were grouped as variant (var) IL26 patients and compared with wild-type (wt) IL26 patients.

### Serum cytokines, complement proteins and free anti-TNF- $\alpha$ levels. Presence of anti-drug antibodies

IL26 levels in serum samples were determined by handling an enzyme-linked immunosorbent assay (ELISA) for human IL26 measurement (Cloud-Clone Corp. Houston, TX) according to the manufacturer's instructions. Sensitivity assays were run to evaluate possible differences between wt and varIL26-genotyped patients and between IL26 either alone or in the presence of bactDNA (Supplementary Fig. 1). Serum TNF- $\alpha$ , IFN- $\gamma$ , and IL-12p40 levels were determined by cytometric bead arrays (CBA) and measured with a FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA).

ELISA kits were also carried out to measure free infliximab and adalimumab levels and to detect anti-drug antibodies (Matriks Biotech, Ankara, Turkey) according to the manufacturer's instructions. Proteins of the complement system C3b, the membrane attack complex (MAC), and C5a were evaluated by MicroVue EIA kits (Quidel Corporation, San Diego, CA) in serum samples of CD patients according to manufacturer's instructions, as previously described [23]. All samples were tested in triplicate and read in a Sunrise Microplate Reader (Tecan, Männedorf, Switzerland). The detection limits for each cytokine assay varied between 2 and 5 pg/mL, between 10 and 30 ng/mL in the case of free anti-TNF- $\alpha$  kits, and between 5 and 8 pg/mL for the complement protein assays. Standard curves were generated for every plate, and the average zero standard optical densities were subtracted from the rest of the standards and samples to obtain a corrected concentration for all parameters. The presence of anti-drug antibodies was evaluated by a cut-off value estimated by multiplying the optical density (OD) of the zero standard by 3, as indicated by the manufacturer's. Samples were considered positive when the ratio sample OD/zero standard OD was higher than 3.

### Peripheral blood mononuclear cell killing assays

To evaluate blood PBMC bactericidal activity, cells from a subset of wtIL26 and varIL26 genotyped patients were

isolated and seeded left untreated or treated with anti-IL26 or an anti-IgG2 isotype control (Sigma-Aldrich, Madrid, Spain) for a 48h period. Following this incubation,  $2.5 \times 10^6$  cells were washed and exposed to the same amount of *E. coli* ( $10^4$  CFU; serotype 0111:B4). The killing assay was performed at 37 °C in a shaker at 15 rpm for 20 min to measure the basal capacity of PBMCs to ingest bacteria before killing occurred (T0), or 2 h to measure the real PBMC killing ability (T2). Extracellular *E. coli* were thoroughly washed and subjected to a 30% sucrose centrifugation to better eliminate bacteria. Cells were resuspended in PBS 5% serum and then diluted in sterile water, to be seeded in agar plates at the estimated dilution ratio. Plates were left 24 h at 37 °C and colony-forming units counted afterwards.

### Cell cultures

PBMCs from patients without bactDNA not receiving biologics or immunosuppressors were washed with phosphate-buffered saline (PBS) at 4 °C. Viability of isolated cells was evaluated by trypan blue staining (Sigma, Madrid, Spain). Cells were resuspended in phenol red-free RPMI 1640 medium (Gibco BRL, Life Technologies, Paisley, UK) supplemented with 10% human serum AB (BioWhittaker, Walkersville, Maryland, USA). PBMCs ( $1 \times 10^6$  cells/well) were incubated with the following: (a) infliximab ( $100 \mu\text{g}/\text{mL}/10^6$  cells) (infliximab was kindly provided by Merck Sharp and Dohme of Spain MSD, Madrid, Spain) plus *E. coli* DNA ( $200 \text{ ng}/\text{mL}/10^6$  cells) for 48h; (b) recombinant human IL26 (R&D Systems) ( $100 \text{ ng}/1 \times 10^6$  cells) plus *E. coli* DNA ( $200 \text{ ng}/\text{mL}/10^6$  cells) for 24 h.

### Statistical analysis

Continuous variables were reported as mean  $\pm$  standard deviation or 95% confidence interval, and categorical variables were expressed as frequencies and percentages. Differences between patient groups were analyzed using the *U*-Mann Whitney test for quantitative data and Chi-square test for qualitative data. The Kolmogorov–Smirnov test was used to test normality of continuous variables. Statistical differences were analyzed using the  $\chi^2$  test for categorical data, and analysis of variance (ANOVA) test for quantitative data followed by the post hoc Bonferroni correction for multiple comparisons. Quantitative data showing non-normal distribution were analyzed using the Mann–Whitney *U* test or Kruskal–Wallis test followed by pairwise comparisons using the Mann–Whitney *U* test with the post hoc Bonferroni correction for multiple comparisons. Bivariate correlations were analyzed using the Spearman test. Statistical significance was considered at *p*-values less than 0.05. Statistical analysis was performed using SPSS v15 and R software.

## Results

### Characteristics of patients

Three hundred and thirteen CD patients in remission were included in the study. Clinical and analytical characteristics of patients are shown in Table 1. Briefly, mean age was  $42 \pm 15$  years and 54% were male. Mean CDAI was  $83.6 \pm 32.8$ , and mean fecal calprotectin was  $52.4 \pm 34.8$   $\mu\text{g/g}$ . These parameters, along with ESR and CRP levels shown in Table 1, confirm clinical remission in our series of patients. Forty percent of patients were active smokers and 25% had a history of previous surgery. Ileal disease was present in 45% of patients, whereas colonic or ileo-colonic disease was present in 50% of patients. Twenty-one percent of patients presented with perianal disease. Twenty-eight percent of patients were on anti-TNF, either alone or combined, and 55% were receiving immunosuppressors.

### BactDNA translocation and IL26 SNP distribution in CD patients

One hundred and six patients had bactDNA fragments in the blood (33.8%). Supplementary Table 1 presents sequencing analysis showing the identified bacterial species and the amount of amplified bactDNA for each species. BactDNA belonged to the *Enterobacteriaceae* family in 78% of patients. The amount of amplified bactDNA was not significantly different between species, family, or gram distribution.

*IL26* SNP distribution of genotypes and allelic frequencies among included patients can be followed in Table 2. All variants were found to be in the Hardy–Weinberg equilibrium in the controls. Variant *IL26* (*varIL26*)-genotyped patients ( $n = 223$ ) were defined as carrying any of the three variants studied either in homozygosity or heterozygosity compared with patients with a wild-type (wt) *IL26* genotype ( $n = 90$ ). The rate of bactDNA translocation in *varIL26*-genotyped patients was similar to that present in *wtIL26*-genotyped patients (33.6 vs 34.4%,  $p = \text{ns}$ ). No significant clinical or analytical differences were found among included CD patients distributed either by bactDNA translocation or *IL26* genotype (data not shown).

### IL26 serum levels respond to systemic bactDNA translocation

The presence of circulating bactDNA was associated with significantly increased levels of IL26 regardless of *IL26* genotype status compared with bactDNA-negative patients ( $101.6 \pm 25.4$  vs  $18.9 \pm 11.2$ ,  $p = 0.001$ ). This elevation was blunted in patients with *varIL26* genotype (Fig. 1a).

The amount of bactDNA was significantly increased in *varIL26* vs *wtIL26* patients ( $26.9 \pm 6.0$  vs  $30.8 \pm 7.2$ ,  $p = 0.01$ ). The overall correlation between amplified bactDNA concentration in patients with bactDNA and IL26 serum levels was statistically significant although weak ( $r = 0.37$ ;  $p = 0.01$ ). This correlation significantly improved when only *wtIL26* patients were considered ( $r = 0.77$ ;  $p = 0.001$ ). The correlation between both variables was lost when patients with a *varIL26* genotype ( $r = 0.08$ ;  $p = 0.476$ ) were considered (Fig. 1b). These results were confirmed in vitro in PBMCs from wt and *varIL26* patients exposed to different concentrations of *E. coli* bactDNA (Fig. 1c).

### Functional capacity of PBMCs to kill bacteria is decreased in *varIL26*-genotyped patients

These results suggest that PBMC interaction with bacteria is compromised in *varIL26*-genotyped patients. To confirm this, killing capacity of PBMCs from a subset of bactDNA-negative patients was evaluated. Figure 2 shows that *wtIL26*-genotyped patients' PBMCs are able to significantly reduce the total CFU counts 2 h after exposure to *E. coli*. However, the presence of a *varIL26* genotype significantly worsens PBMC killing capacity, as total CFU count significantly increases at 2 h in comparison to *wtIL26*-genotyped PBMCs. In addition, preincubation of PBMCs from *wtIL26* and *varIL26*-genotyped patients with anti-IL26 further reduces PBMC killing capacity.

### The soluble inflammatory response to bactDNA is sensitive to *IL26* genotype

We then evaluated the soluble inflammatory response to bactDNA in patients distributed by *IL26* genotype. Serum levels of proinflammatory mediators in patients without bactDNA were as follows: TNF- $\alpha$  [ $44.4 \pm 29.8$  pg/mL], IFN- $\gamma$  [ $102.2 \pm 68.5$  pg/mL], and IL-12 [ $194.3 \pm 70.4$  pg/mL]. These levels significantly increased both in *wtIL26* and *varIL26* patients with bacterial DNA (Fig. 3a). However, the variant genotype was associated with significantly further increased levels of all three cytokines compared to *wtIL26*-genotyped patients with bactDNA. To support this result, serum levels of complement proteins were measured and showed a significant increase in the overall series of patients with vs without bactDNA (Supplementary Table 2). The presence of a *varIL26* further increased complement protein levels in patients with bactDNA compared to *wtIL26*-genotyped patients.

We then cultured PBMCs from bactDNA-negative patients distributed by *IL26* genotype with human recombinant IL26 and *E. coli* DNA. Cytokine levels were

**Table 1** Clinical and analytical characteristics of patients


	Patients ( <i>n</i> = 313)
Age (years)	42 ± 15
Weight (kg)	70.24 ± 14.86
Gender (male/female), <i>n</i> (%)	167 (53.4%)/146 (46.6%)
Smoking habit (yes/no/ex), <i>n</i> (%)	126 (40.2%)/119 (38.0%)/68 (21.8%)
Disease duration (months)	115.15 ± 114.55
Resection, <i>n</i> (%)	71 (22.6%)
CDAI	83.6 ± 32.8
Montreal A (age of onset), <i>n</i> (%)	
A1 (≤ 16)	18 (5.8%)
A2 (17–40)	219 (70.0%)
A3 (> 40)	76 (24.2%)
Montreal L (location), <i>n</i> (%)	
L1	143 (45.6%)
L2	70 (22.3%)
L3	86 (27.4%)
L4	14 (4.5%)
Montreal B (behavior), <i>n</i> (%)	
B1 (non-stricturing, nonpenetrating)	151 (48.2%)
B1p (non-stricturing, nonpenetrating, penetrating perianal disease)	40 (12.8%)
B2 (stricturing)	49 (15.6%)
B2p (stricturing, perianal disease associated)	14 (4.5%)
B3 (penetrating)	45 (14.4%)
B3p (penetrating, penetrating perianal disease)	14 (4.5%)
Therapy, <i>n</i> (%)	
Mesalazine	70 (22.4%)
Azathioprine	104 (33.2%)
Metotrexate	9 (2.9%)
Mesalazine and azathioprine	17 (5.4%)
Mesalazine and steroids	4 (1.3%)
Azathioprine + steroids	4 (1.3%)
Metotrexate + steroids	1 (0.3%)
Infliximab	27 (8.6%)
Adalimumab	29 (9.3%)
Infliximab + azathioprine	16 (5.1%)
Adalimumab + azathioprine	11 (3.5%)
Infliximab + steroids	2 (0.6%)
Adalimumab + steroids	4 (1.4%)
Infliximab + metotrexate	2 (0.6%)
Infliximab + azathioprine + steroids	1 (0.3%)
No therapy	12 (3.8%)
CRP (mg/dL)	0.58 ± 1.10
Fecal calprotectin (μg/g)	52.40 ± 34.80
ASCAs, <i>n</i> (%)	118 (39.6%)
Hemoglobin (g/dL)	13.95 ± 2.35
ESR (mm)	19.3 ± 15.4
Albumin (g/dL)	4.12 ± 4.50
Total WBCs (mm <sup>3</sup> )	6892.5 ± 2636.8
Temperature (°C)	36.07 ± 0.22
Pulse rate (bpm)	70.68 ± 6.11

**Table 2** Allelic frequencies of *IL26* SNPs in included CD patients

Genotype	n (%) patients/controls		Variant allele frequency (%)	
	Homozygous wild-type	Heterozygous	Homozygous variant	Variant allele frequency (%)
IL26 rs1558744 (A > G)	55 (17.5%)/88 (17.5%)	178 (56.8%)/229 (45.5%)	80 (25.5%)/186 (37.0%)	53.9/59.7
IL26 rs2870946 (T > C)	243 (77.6%)/431 (85.7%)	67 (21.4%)/68 (13.5%)	3 (0.9%)/4 (0.8%)	11.6/7.6
IL26 rs7134599 (G > A)	88 (28.1%)/208 (41.4%)	170 (54.3%)/76 (15.1%)	55 (17.5%)/219 (43.5%)	44.7/36.9


significantly higher in the supernatants of PBMCs cultured with bacterial DNA from *varIL26* patients than in *wtIL26* patients (white vs black bars), supporting the in vivo results. The addition of the recombinant IL26 protein was associated with a reduction in pro-inflammatory

cytokine levels in the supernatants of cultured *varIL26* cells to levels present in *wtIL26* cells in response to *E. coli* DNA (Fig. 3b). Supplementary Table 3 shows cytokine levels in the supernatants of cultured PBMCs unstimulated and with human recombinant IL26 alone.



**Fig. 1** Serum IL26 levels in CD patients. **a** Serum IL26 levels in CD patients distributed by *IL26* genotype and the presence of bacterial DNA in blood. **b** Correlation between IL26 serum levels and amplified bactDNA in patients with bactDNA in blood distributed by *IL26* genotype. \* $p < 0.01$  compared with patients without bactDNA;

$p = 0.01$  compared with *wtIL26* with bacterial DNA. **c** IL26 levels in the supernatants of PBMCs from wild-type and variant *IL26*-genotyped patients cultured with increasing amounts of *E. coli* DNA. Figure shows mean  $\pm$  SD from 10 patients from each group. \* $p < 0.01$  compared with *wtIL26*. *wt* wild-type, *var* variant




**Fig. 2** *E. coli* killing assays on blood PBMCs. Total CFUs before ( $T = 0$ ) and 2 h after *E. coli* exposure ( $T = 2$ ) are represented. Results were obtained in experiments using  $2.5 \times 10^6$  cells from 10 wtIL26 and 10 varIL26 patients. \* $p < 0.01$  compared with wtIL26 patients and wtIL26 patients incubated with an IL26 isotype control

**Anti-TNF treatment efficacy is affected by IL26 genotype in patients with bacterial DNA**

As varIL26 was associated with elevated TNF- $\alpha$  concentrations in patients with circulating bactDNA, we studied varIL26 effects on the treatment with anti-TNF- $\alpha$  drugs. Six out of 92 patients on biologics (4 wtIL26 and 2 varIL26) had anti-drug antibodies in the blood and were excluded from this analysis. Figure 4 shows that serum free anti-TNF- $\alpha$  levels in varIL26-genotyped patients were significantly lower than levels in wtIL26-genotyped patients in the presence of bactDNA.

To confirm the further reduction of serum free anti-TNF- $\alpha$  levels associated with a varIL26 genotype and the presence of bactDNA, we cultured PBMCs from bactDNA-negative patients distributed by IL26 genotype with *E. coli* DNA and infliximab (Fig. 5). While TNF- $\alpha$  levels significantly increased,




**Fig. 4** Free anti-TNF- $\alpha$  serum levels in CD patients on biologics distributed by the IL26 genotype and the presence of bactDNA. \* $p < 0.01$  compared with levels in patients without bactDNA.  $\S p < 0.01$  compared with levels in wtIL26-genotyped patients


the concentration of infliximab significantly decreased in the supernatant of cultured cells from patients with a varIL26 genotype stimulated with *E. coli* DNA compared with wtIL26-genotyped patients. IL26 blockade in wtIL26-genotyped patients further increased TNF- $\alpha$  levels in the supernatants and significantly reduced free anti-TNF- $\alpha$  levels. On the contrary, IL26 supplementation to PBMCs from varIL26 patients resulted in the partial restoration of the TNF- $\alpha$  response and available anti-TNF- $\alpha$  levels shown by wtIL26-genotyped patients.

**A varIL26 genotype is associated with the initiation of anti-TNF- $\alpha$  therapy in CD patients in remission**

Patients were followed up for 6 months. None of the patients were lost during the follow-up period. Forty patients relapsed in this time frame, with no differences according to IL26 genotype (11 of 90 wtIL26 [12.2%] patients vs 35 of 223 [15.7%] varIL26 patients,  $p = 0.104$ ). Figure 6 shows the




**Fig. 3 a** Serum levels of TNF- $\alpha$ , IFN- $\gamma$ , and IL-12p40 in CD patients with bactDNA distributed by IL26 genotype. \* $p < 0.01$  compared with serum levels in patients without bactDNA;  $\S p < 0.01$  compared with serum levels in bactDNA + wtIL26 patients. **b** Levels of TNF- $\alpha$ , IFN- $\gamma$ , and IL-12p40 in the supernatants of PBMCs from bactDNA-negative



patients either with recombinant human IL26 or not and cultured with *E. coli* DNA (see methods). Results were obtained in experiments using  $1 \times 10^6$  cells from 10 wtIL26 and 10 varIL26 patients. \* $p < 0.01$  compared with the rest of conditions

**Fig. 5** In vitro analysis of TNF- $\alpha$  and free anti-TNF- $\alpha$  levels in the supernatants of PBMCs from *wtIL26* and *varIL26* patients cultured with *E. coli* DNA (200 ng/mL/10<sup>6</sup> cells) plus infliximab (100  $\mu$ g/mL/10<sup>6</sup> cells) in all cases. Results were obtained in experiments using 1  $\times$  10<sup>6</sup> cells from 10 *wtIL26* and 10 *varIL26* patients. \* $p$  < 0.01 compared with *wtIL26*




percentage of patients who required either initiation, intensification, or switch of biologics. The initiation of biologics, the need for intensification, and switch of biologic drug were more frequent in *varIL26*-genotyped patients. However, the initiation of biologics was the only statistically significant variable between groups.

## Discussion

The present study shows that IL26 is sensitive to bactDNA translocation into blood of CD patients. In addition, a *varIL26* genotype is associated with reduced IL26 serum levels in patients with this circulating antigen and the reduction of PBMC functional capacity to kill bacteria. This might compromise bactDNA clearance, inducing a sustained pro-inflammatory environment, and an increased anti-TNF- $\alpha$  consumption.

Bacterial DNA translocation has been identified as a risk factor of relapse in CD patients in remission. In addition to this, an increased risk of other significant clinical events such as the initiation of steroids or the switch to stepped up treatments has also been associated with the detection of circulating bacterial genomic fragments in the blood of CD patients [9]. Likely, the presence of circulating bactDNA induces the secretion of pro-inflammatory cytokines leading to an increased [1] and dose-dependent production of antimicrobial peptides [24]. Its interaction with the immune system is especially relevant in patients with *NOD2* gene variants, who seem to be predisposed to CD development [25, 26] and may show an impaired response against the translocation of commensal bacterial antigens [8]. These data support that the translocation of bactDNA may be a risk factor for a more severe disease course.

**Fig. 6** Clinical evolution of patients. Initiation, intensification, and switch of biologics among included CD patients during follow-up are represented





IL26, a member of the IL-20 cytokine family and part of the Th17 cell cytokines, has been shown to assemble with bactDNA fragments and promote TLR-9 activation in antigen presenting cells to deliver a pro-inflammatory immune response [14]. This facilitates the clearance of circulating bactDNA and may prevent a sustained inflammatory environment. Several *IL26* SNPs have been described, and we hypothesized that a *varIL26* genotype may affect IL26 interaction with bactDNA and impair the required immune response to resolve this bacterial antigen challenge.

To our knowledge, this is the first study evaluating the effect of *IL26* SNPs in CD patients. We have observed that IL26 levels are significantly increased in patients with bactDNA. However, the presence of a *varIL26* genotype in patients with bactDNA is associated with significantly reduced IL26 levels compared with *wtIL26* patients (Fig. 1). Although a limitation due to untested effect of IL26-DNA complexes on measured IL26 serum levels may be considered, these results suggest first that IL26 production depends in part on the presence of circulating bactDNA in CD patients. In fact, a positive correlation between IL26 and the amount of amplified bactDNA is present in *wtIL26*-genotyped patients, indicating that this cytokine participates in defense programs against bacterial challenges mediated by Th17 responses [27, 28]. Secondly, that the clearance of bactDNA in these patients may be affected by the presence of a *varIL26* genotype, which may partially explain the observed genetic susceptibility to CD in patients with SNPs in the *IL26* region [16]. In addition, the concentrations of the pro-inflammatory cytokines TNF- $\alpha$ , IFN- $\gamma$ , and IL-12 are significantly increased in bactDNA-positive CD patients with a *varIL26* genotype (Figure 3a). Potentially, the increased exposure of bactDNA could stimulate the innate immune machinery, in which activated macrophages are recruited, the complement cascade is initiated, and endothelial cells are activated to induce TNF- $\alpha$  and other inflammatory mediators that further contribute to sustain an upheld pro-inflammatory environment [29]. In agreement with this, complement proteins are significantly increased in response to bactDNA in patients with a *varIL26* genotype compared to patients with a *wtIL26* genotype.

The relevance of an increased systemic immune response in CD patients may be reflected in their need for intensified anti-TNF- $\alpha$  therapy. In the present investigation, the significant reduction in serum TNF- $\alpha$  levels in patients on biologics was only achieved in *wtIL26*-genotyped patients. In consequence, we found that free anti-TNF- $\alpha$  trough levels are significantly reduced in *varIL26* patients (Fig. 4). To model the in vivo situation in vitro, PBMCs from patients without bactDNA were stimulated with *E. coli* in the presence of infliximab. Cultures of PBMCs from *varIL26* patients showed significantly lower amounts of free anti-TNF- $\alpha$  of PBMCs from *wtIL26* patients (Fig. 5).

From a clinical point of view, the classification of CD patients by their *IL26* genotype could be of interest, not only in terms of their predisposition to an exacerbated inflammatory response, as they may be exposed to longer antigen circulation in the case of bacterial translocation, but also for the identification of patients who might respond worse to established drug schedules. In fact, the percentage of patients who required initiation of anti-TNF- $\alpha$  was significantly higher in *varIL26* vs *wtIL26*-genotyped patients (Fig. 6). Also, an increased percentage of *varIL26* patients included in our series, compared to *wtIL26* patients, required intensification or switch of biologic drug, although probably larger series of patients would be necessary to find a statistically significant association. Although results in this regard are merely exploratory and present several limitations that would require a specifically designed study, these patients might benefit from early therapies in the so-called top-down approach [30, 31], especially those subgroups with translocation of bacterial DNA, *NOD2*, or other CD-related gene variants.

In summary, IL26 participates in the modulation of the pro-inflammatory soluble response in CD patients in remission with bactDNA translocation. However, the presence of a *varIL26* genotype is associated with a reduced PBMC functional capacity to kill bacteria, the stimulation of an exacerbated inflammatory response, and the increment of anti-TNF- $\alpha$  consumption in these patients. These results may help in explaining the identification of bactDNA in blood as an independent risk factor of flare at short term in CD patients. Further studies on IL26 signaling restoration may provide new therapeutic approaches to control bacterial translocation and inflammation in this subgroup of CD patients.

**Acknowledgements** This work was supported by Asociación Española de Gastroenterología. J.H.N is supported by the Swiss National Foundation (SNSF 310030\_146290).

**Compliance with ethical standards** The Ethics Committee of Hospital General Universitario de Alicante approved the study protocol.

**Conflict of interest** The authors declare that they have no conflicts of interest.

## References

1. Gutierrez A, Frances R, Amoros A, Zapater P, Garmendia M, Ndongo M, Cano R, Jover R, Such J, Perez-Mateo M (2009) Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. *Inflamm Bowel Dis* 15:508–514
2. Gutierrez A, Holler E, Zapater P, Sempere L, Jover R, Perez-Mateo M, Schoelmerich J, Such J, Wiest R, Frances R (2010) Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. *Inflamm Bowel Dis* 17(8):1641–1650
3. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT (2005) Experimental models of inflammatory bowel

- disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. *Immunol Rev* 206:260–276
4. Obermeier F, Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N, Hedrich HJ, Aschenbrenner E, Schlegelberger B, Rogler G et al (2005) CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. *Gastroenterology* 129:913–927
  5. Podolsky DK (2002) Inflammatory bowel disease. *N Engl J Med* 347:417–429
  6. Sartor RB (1997) Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. *Am J Gastroenterol* 92:5S–11S
  7. Abraham C, Medzhitov R (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology* 140:1729–1737
  8. Gutierrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, Gonzalez-Navajas JM, Such J, Wiest R, Rogler G et al (2014) Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. *Gut* 63:272–280
  9. Gutierrez A, Zapater P, Juanola O, Sempere L, Garcia M, Laveda R, Martinez A, Scharl M, Gonzalez-Navajas JM, Such J et al (2016) Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with Crohn's disease. *Am J Gastroenterol* 111:529–540
  10. Calderon-Gomez E, Bassolas-Molina H, Mora-Buch R, Dotti I, Planell N, Esteller M, Gallego M, Marti M, Garcia-Martin C, Martinez-Torro C et al (2016) Commensal-specific CD4(+) cells from patients with Crohn's disease have a T-helper 17 inflammatory profile. *Gastroenterology* 151(489–500):e483
  11. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. *Nat Rev Immunol* 14:585–600
  12. Dambacher J, Beigel F, Zitzmann K, De Toni EN, Goke B, Diepolder HM, Auernhammer CJ, Brand S (2009) The role of the novel Th17 cytokine IL26 in intestinal inflammation. *Gut* 58:1207–1217
  13. Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov A et al (2004) Cutting edge: IL26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. *J Immunol* 172:2006–2010
  14. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T et al (2015) TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. *Nat Immunol* 16:970–979
  15. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut* 61:1693–1700
  16. Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W et al (2009) Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. *Nat Genet* 41:216–220
  17. Padua D, Mahurkar-Joshi S, Law IK, Polyarchou C, Vu JP, Pisegna JR, Shih D, Iliopoulos D, Pothoulakis C (2016) A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation. *Am J Physiol Gastrointest Liver Physiol* 311:G446–G457
  18. Vandembroeck K, Cunningham S, Goris A, Alloza I, Heggarty S, Graham C, Bell A, Rooney M (2003) Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. *Arthritis Rheum* 48:2773–2778
  19. Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. *Gastroenterology* 126:1518–1532
  20. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA et al (2015) A global reference for human genetic variation. *Nature* 526:68–74
  21. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. *Can J Gastroenterol* 19(Suppl A):5–36
  22. Frances R, Benlloch S, Zapater P, Gonzalez JM, Lozano B, Munoz C, Pascual S, Casellas JA, Uceda F, Palazon JM et al (2004) A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. *Hepatology* 39:484–491
  23. Frances R, Gonzalez-Navajas JM, Zapater P, Munoz C, Cano R, Pascual S, Marquez D, Santana F, Perez-Mateo M, Such J (2007) Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. *J Clin Immunol* 27:438–444
  24. Gutierrez A, Holler E, Zapater P, Sempere L, Jover R, Perez-Mateo M, Schoelmerich J, Such J, Wiest R, Frances R (2011) Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. *Inflamm Bowel Dis* 17:1641–1650
  25. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411:603–606
  26. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411:599–603
  27. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. *Nature* 453:1051–1057
  28. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Janniere L et al (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. *J Exp Med* 205:1543–1550
  29. Mak TW, Saunders ME (2011) *Innate Immunity Primer to the immune response* Elsevier. The Netherlands, Amsterdam, pp 41–58
  30. Fasci Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C (2012) Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? *J Gastrointest Liver Dis* 21:67–73
  31. Rogler G (2013) Top-down or step-up treatment in Crohn's disease? *Dig Dis* 31:83–90